Reevaluace stagingu nodálního statusu nemalobuněčného karcinomu plic (NSCLC) levého horního laloku v intencích revidovaných ESTS doporučení a našich zkušeností
| Title in English | Staging re-evaluation of the nodal status of non-small cell lung carcinoma (NSCLC) of the left upper lobe based on revised ESTS guidelines and our experience |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Onkologie |
| MU Faculty or unit | |
| Citation | |
| Field | Surgery incl. transplantology |
| Keywords | Non-small cell lung carcinoma; left upper lobe; staging; neoadjuvant therapy; surgical treatment. |
| Description | Staging and re-staging of non-small cell lung carcinoma of the left upper lobe represents a multidisciplinary challenge for diagnostics and therapy of this serious disease. Neoadjuvant therapy is an established therapeutic approach for multimodal therapy of non-small cell lung carcinoma with pre-surgery diagnosed nodal spreading into the mediastinal compartment. The autonomy of lymphatic drainage of the upper left lobe causes that the cancer cells produce primary lymphatic metastases in the aorta-pulmonary (A-P) window area. These lymphatic nodes are also a part of nodal compartment of the mediastinum. However, they are localized beyond the reach of the conventional staging methods. Therefore, even in spite of negative mediastinoscopy and CT, N2 spreading into the A-P window area can be proven intra-operationally. Establishment of invasive staging during suspected positivity of the A-P window nodes might be of therapeutic benefit for selected patients, in terms of primary induction therapy prior to surgical resection. The aim of this review is to pinpoint and highlight the known issues with staging and re-staging of non-small cell lung carcinoma of the upper left lobe based on revised guidelines of the European Association of Thoracic Surgery and our experience. |